Clinical trial
A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes…
NCT00246987 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00246987 |
|---|---|
| Title | A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control |
| Official title | A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Type 2 |
| Intervention type | Drug |
| Interventions | Muraglitazar |
| Enrollment | 341 |
| Start date | Jun 1, 2003 |
| Completion | Apr 1, 2004 |
| First posted | Nov 1, 2005 |
| Last update posted | Apr 27, 2012 |
| Countries | Australia, Canada, Mexico, Poland, Puerto Rico, Taiwan, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: